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Abstract
Objectives: The study sought to assess the impact of statin therapy on survival in patients presenting with ventricular
tachyarrhythmias.
Background: Data regarding the outcome of patients with statin therapy presenting with ventricular tachyarrhythmias
is limited.
Methods: A large retrospective registry was used including all consecutive patients presenting with ventricular
tachycardia (VT) or fibrillation (VF) from 2002 to 2016. Patients with statin were compared to patients without
statin therapy (non-statin). The primary prognostic endpoint was long-term all-cause death at 3 years. Uni- and
multivariable Cox regression analyses were applied in propensity-score matched cohorts.
Results: A total of 424 matched patients was included. The rates of VT and VF were similar in both groups (VT: statin 71%
vs. non-statin 68%; VF: statin 29% vs. 32%; p= 0.460). Statin therapy was associated with lower all-cause mortality at long-
term follow-up (mortality rates 16% versus 33%; log rank, p= 0.001; HR = 0.438; 95% CI 0.290–0.663; p= 0.001), irrespective
of the underlying type of ventricular tachyarrhythmia (VT/VF), left ventricular ejection fraction (LVEF) > 35%, presence of an
activated implantable cardioverter defibrillator (ICD), cardiogenic shock or cardiopulmonary resuscitation (CPR).
Conclusion: Statin therapy is independently associated with lower long-term mortality in patients presenting with
ventricular tachyarrhythmias on admission.
Trial registration: Clinicaltrials.gov, NCT02982473, 11/29/2016, Retrospectively registered.
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Condensed abstract
This study retrospectively examined the impact of a statin
therapy on survival in 424 propensity-matched patients ad-
mitted with ventricular tachyarrhythmias. Presence of statin
therapy was independently associated with lower long-term
mortality (mortality rates 16% versus 32%; log rank
p= 0.001; HR = 0.438; 95% CI 0.290–0.663; p= 0.001).
Introduction
Epidemiological studies demonstrated a distinct asso-
ciation between cholesterol levels and all-cause as
well as cardiovascular mortality [1–4]. Therefore,
international guidelines recommend lipid-lowering
therapy in patients at risk for and with already estab-
lished cardiovascular diseases (CVD) as an effective
treatment for secondary and primary prevention of
atherosclerotic cardiovascular disease. Statins com-
petitively inhibit HMG-CoA reductase activity and
currently represent the first-line therapy in lowering
lipid-levels [3, 5].
Large, randomized controlled trials (RCT) in patients
with acute myocardial infarction (AMI) or coronary
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: michael.behnes@umm.de
†Jonas Rusnak and Michael Behnes contributed equally to this work.
1First Department of Medicine, University Medical Centre Mannheim (UMM),
Faculty of Medicine Mannheim, University of Heidelberg, European Center
for AngioScience (ECAS), and DZHK (German Center for Cardiovascular
Research) partner site Heidelberg/Mannheim, Mannheim, University of
Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
Full list of author information is available at the end of the article
Rusnak et al. Lipids in Health and Disease          (2019) 18:119 
https://doi.org/10.1186/s12944-019-1011-x
artery disease (CAD) demonstrated that lipid lowering
therapy by statins (i.e. simvastatin or pravastatin), was
associated with a reduced all-cause and cardiovascular
mortality at five to six years [6, 7]. Furthermore, statin
therapy was also investigated as an adjunct therapy in
patients with chronic heart failure due to any cause.
However, within the RCTs, namely GISSI-HF and COR-
ONA, the use of rosuvastatin was not associated with a
reduction of mortality or sudden cardiac death (SCD) at
three to four years [8, 9]. The authors based their study
concept on the multiple mechanisms of statins beyond
prevention in artheroslerosis and therefore included any
kind of heart failure patients without any strict inclusion
criteria independently of cholesterol cutoffs for the use
of rosuvastatin [10].
The multiple mechanisms of statins beyond lipid-lowering
have been described recently and may include additional
anti-arrhythmic effects. Statins stabilize the atherosclerotic
and ischemic burden, which might indirectly translate into
anti-arrhythmic effects inhibiting the onset of ventricular
tachyarrhythmias and SCD. A direct antiarrhythmic effect
apart from affecting arterosclerosis has also been suggested
[11, 12]. Several observational studies investigating mostly
patients with heart failure showed a reduction of rates of
ventricular tachycardia (VT), ventricular fibrillation (VF)
and SCD, as well as reduced rates of appropriate
ICD-therapy, which might in turn impact secondary reduc-
tion of mortality due to ventricular tachyarrhythmias [10,
13–20]. However, no data is available at present, whether
statins may impact secondary long-term survival in patients
after presenting with ventricular tachyarrhythmias on
admission.
Therefore, the present study evaluates the prognostic
impact of statin therapy on long-term survival in patients
presenting with ventricular tachyarrhythmias on admission.
Methods
Study patients, design and data collection
The present study retrospectively included all consecu-
tive patients presenting with ventricular tachyarrhyth-
mias on hospital admission from 2002 until 2016 at
the First Department of Medicine, University Medical
Centre Mannheim, Germany. Using the hospital infor-
mation system, all relevant clinical data related to the
index event were documented. The data, analytic
methods, and study materials will be made available to
other researchers for purposes of reproducing the results
or replicating the procedure onreasonable personal re-
quest to the corresponding author.
Ventricular tachyarrhythmias comprised VT and VF, as
defined by current international guidelines [21]. Sustained
VT was defined by duration of more than 30 s or causing
hemodynamic collapse within 30 s. Non-sustained VT was
definded by duration of less than 30 s both with wide QRS
complex (≥120 milliseconds) at a rate greater than 100 beats
per minute [21]. Ventricular tachyarrhythmias were docu-
mented by 12-lead ECG (electrocardiography), ECG tele-
monitoring, ICD or in case of unstable course or during re-
suscitation pulmonary resuscitation (CPR) by external defib-
rillator monitoring. Documented VF was treated by external
defibrillation and in case of prolonged instability with add-
itional intravenous anti-arrhythmic drugs during CPR.
Further data being documented contained baseline char-
acteristics, prior medical history, prior medical treatment,
length of index stay, detailed findings of laboratory values
at baseline, data derived from all non-invasive or invasive
cardiac diagnostics and device therapies, such as coronary
angiography, electrophysiological examination, data being
derived from prior or newly implanted cardiac devices,
including those ICD already implated at index and at
follow-up, pacemakers or cardiac contractility modulation
(CCM), as well as imaging modalities, such as echocardiog-
raphy or cardiac magnetic resonance imaging (cMRI).
Every revisit at the outpatient clinic or
re-hospitalization was documented when related to re-
current ventriculartachyarrhythmias and adverse cardiac
events. Adverse cardiac events comprised acute heart
failure, CPR, cardiac surgery, recurrent percutaneous
coronary intervention, new implants or upgrades of car-
diac devices, and worsening or improvement of left ven-
tricular function.
Documentation period lasted from index event until
2016. Documentation of all medical data was performed
by independent cardiologists at the time of the patients’
individual period of clinical presentation, being blinded
to final data analyses.
The present study is derived from an analysis of the
“Registry of Malignant Arrhythmias and Sudden Cardiac
Death - Influence of Diagnostics and Interventions
(RACE-IT)” and represents a single-center registry including
consecutive patients presenting with ventricular tachyar-
rhythmias, being acutely admitted to the University Medical
Center Mannheim (UMM), Germany (clinicaltrials.gov iden-
tifier: NCT02982473) from 2002 until 2016. The registry
was carried out according to the principles of the declaration
of Helsinki and was approved by the medical ethics com-
mission II of the Faculty of Medicine Mannheim, University
of Heidelberg, Germany.
The medical center covers a general emergency depart-
ment for emergency admission of traumatic, surgical,
neurological and cardiovascular conditions. Interdisciplin-
ary consultation is an inbuilt feature of this 24/7 service,
and connects to a stroke unit, four intensive care units
(ICU) with extracorporeal life support and a chest pain unit
(CPU) to alleviate rapid triage of patients. The cardiologic
department itself includes a 24 h catheterization laboratory,
an electrophysiologic laboratory, a hybrid operating room
and telemetry units.
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Index events, risk stratification measures and prognostic
outcome
For the present study, all patients surviving index
hospitalization after presenting with ventricular tachyar-
rhythmias between 2002 and 2016 were included. Each
patient was counted only once for inclusion when pre-
senting with the first episode of ventricular tachyar-
rhythmias. Indication to treat patients with statins was
based on European guidelines of statin therapy [3]. Over-
all exclusion criteria comprised patients without
complete follow-up data regarding mortality.
The primary prognostic endpoint was all-cause mortal-
ity during the follow-up period until 2016. All-cause mor-
tality was documented using our electronic hospital
information system and by directly contacting state resi-
dent registration offices (“bureau of mortality statistics”)
across Germany. Identification of patients was verified by
name, surname, day of birth and registered living address.
In 48 patients, no data on patients’ survival could have
been retrieved, as those patients were not even reachable
by telephone, and were therefore excluded from final ana-
lyses (corresponding lost to follow-up rate of 1.7%).
Statistical methods
Quantitative data are presented as mean ± standard error
of mean (SEM), median and interquartile range (IQR),
and ranges depending on the distribution of the data
and were compared using the Student’s t test for nor-
mally distributed data or the Mann-Whitney U test for
nonparametric data. Deviations from a Gaussian distri-
bution were tested by the Kolmogorov-Smirnov test.
Spearman’s rank correlation for nonparametric data was
used to test univariate correlations. Qualitative data are
presented as absolute and relative frequencies and com-
pared using the Chi2 test or the Fisher’s exact test, as
appropriate.
The following analyses were applied stepwise to evalu-
ate the prognostic impact of statin therapy on all-cause
mortality:
Propensity score analyses were performed, since this
study includes consecutively all patients with ven-
tricular tachyarrhythmias without randomization [22,
23]. Accordingly, propensity scores (probability for
belonging to statin = yes) were calculated for each in-
dividual based predefined variables (see below). After-
wards, matched pairs were created using the method
of nearest neighbor matching with a caliper distance
of 5%. This means: each pair consisted of one individ-
ual with statin = yes and statin = no, whose propensity
scores differed by less than 5%. We found 212 pairs
with mean propensity score 0.5931 +/− 0.3113 (statin
therapy = 0) and 0.6065 +/− 0.3121 (statin therapy = 1).
Uni-variable stratification was performed using the
Kaplan-Meier method with comparisons between groups
using uni-variable hazard ratios (HR) given together with
95% confidence intervals, according to the presence of a
statin therapy within the propensity-matched cohorts.
Multivariable Cox regression models were developed
using the “forward selection” option, where only statisti-
cally significant variables (p < 0.05) were included and
analyzed simultaneously (see below). Multivariable Cox
regressions were applied in the propensity-matched
cohorts.
Predefined variables being used for propensity score
matching (step A) and multivariable Cox-regressions
(step C) included: baseline parameters (age, gender),
chronic diseases (diabetes, chronic kidney disease (glom-
erular filtration rate < 90mL/min/1. 73m2), left ventricu-
lar dysfunction), acute comorbidities (cardiogenic shock,
cardiopulmonary resuscitation (CPR), acute myocardial
infarction), presence of an implanted cardiac defibrillator
(ICD), and underlying ventricular tachyarrhythmia (i.e.
VT/VF) on admission.
Follow-up periods for evaluation of all-cause mortality
were set at 3 years (=long-term), according to the me-
dian survival of statin patients to guarantee complete
survival of at least 50% of patients. Patients not meeting
long-term follow-up were censored.
The result of a statistical test was considered signifi-
cant for p < 0.05, and a statistical trend for p < 0.10. SAS,
release 9.4 (SAS Institute Inc., Cary, NC, USA) and SPSS
(Version 25, IBM, Armonk, New York) were used for
statistics.
Results
Study population
The propensity-matched cohort of consecutive patients
surviving ventricular tachyarrhythmias on admission at
our institution consisted of a total of 424 patients, of
which each half was treated either with or without sta-
tins. The cohort was well matched for age, gender, arter-
ial hypertension and diabetes. Statin patients revealed a
higher rate of hyperlipidaemia, smoking and prior his-
tory of myocardial infarction. Overall, most patients pre-
sented with VT compared to VF with equally distributed
rates in each group (VT: 71% versus 68%; VF: 29% ver-
sus 32%) (Table 1).
Target dosages were reached already at discharge, in-
cluding simvastatin as the most frequently administered
statin (n = 105; 50%; mean dosage 29 mg per day)
followed by atorvastatin (n = 86; 41%; mean dosage 40
mg per day), fluvastatin (n = 10; 5% mean dosage 56 mg
per day) and pravastatin (n = 8; 4%; mean dosage 21mg
per day) (data not shown).
Notably, no differences were found in both groups re-
garding prognosis-relevant comorbidities, including
AMI, cardiogenic shock, cardiomyopathy, PEA (pulseless
electrical activity) or asystole. Statin patients suffered
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less often from clinical significant bleeding and anaemia
(Table 1).
Cardiac diagnostics and therapies
As shown in Table 2, notably no differences were found in
both groups regarding LVEF, rates of CPR, external defib-
rillation, fibrinolysis and TTM (targeted temperature
management). Additionally, no differences were observed
regarding extend of CAD and PCI rates, rates of electro-
physiological testing and device therapy. CABG (coronary
artery bypass graft) was more common in statin patients,
alongside with higher rates of treatment with beta-blocker,
ACEi (angiotensin-converting-enzyme inhibitor), ASA
(acetylsalicylic acid), and dual antiplatelet therapy (Table
2).
All-cause mortality and survival data
At long-term follow up (median 3.0 years (IQR 638 days
– 2869 days), statin patients had significantly better
survival compared to non-statin patients (long-term
mortality rates 16% versus 33%; log rank p = 0.001; HR
= 0.438; 95% CI 0.290–0.663; p = 0.001); (Fig. 1, left
panel). Focusing on the presence of ventricular tachyar-
rhythmias, the prognostic benefit of statin patients was
irrespective of the presence of VT (mortality rates 15%
versus 33%; log rank p = 0.001; HR = 0.439; 95% CI
0.267–0.723; p = 0.001) (Fig. 1, middle panel) or VF
(mortality rates 16% versus 34%; log rank p = 0.028; HR
= 0.445; 95% CI 0.212–0.935; p = 0.032) (Fig. 1, right
panel). Accordingly, long-term survival was not statisti-
cally different in statin patients presenting with VF
compared to VT (mortality rates 16% versus 15%; log
rank p = 0.796) (data not shown).
The prognostic benefit of statin patients was still evi-
dent when stratifying according to left ventricular ejec-
tion fraction (LVEF) above or below 35% (mortality
rates: LVEF ≥35, 11% vs 32%, log-rank p = 0.001, HR =
Table 1 Baseline characteristics and comorbidities after
propensity score matching
Characteristic Non statin
(n = 212; 50%)
statin
(n = 212; 50%)
p value
Age, median (range) 69 (16–92) 68 (25–86) 0.669
Gender, n (%)
Male 159 (75) 164 (77) 0.569
Ventricular tachyarrhythmias, n (%)
Ventricular tachycardia 144 (68) 151 (71) 0.460
Ventricular fibrillation 68 (32) 61 (29)
Prior medical history, n (%)
Chronic heart failure 71 (34) 72 (34) 0.918
Coronary artery disease 102 (48) 102 (48) 1.000
Myocardial infarction 49 (23) 67 (32) 0.050
Prior PCI 41 (19) 58 (27) 0.051
Prior CABG 25 (12) 43 (20) 0.017
Inflammatory heart disease 2 (0.9) 3 (1) 1.000
Valvular heart disease 30 (14) 21 (10) 0.179
Implanted cardiac devices
ICD 40 (19) 38 (18) 0.802
Pacemaker 10 (5) 9 (4) 0.814
Ablation therapy 10 (5) 4 (2) 0.103
Stroke 23 (11) 25 (12) 0.759
Chronic kidney disease 106 (50) 103 (49) 0.771
Liver cirrhosis 3 (1) 1 (0.5) 0.623
COPD/asthma 29 (14) 21 (10) 0.228
Cardiovascular risk factors, n (%)
Arterial hypertension 124 (59) 141 (67) 0.088
Diabetes mellitus 56 (26) 55 (26) 0.912
Hyperlipidemia 41 (19) 101 (48) 0.001
Smoking 51 (24) 72 (34) 0.025
Cardiac family history 25 (12) 22 (10) 0.643
Comorbidities at index stay, n (%)
Acute myocardial infarction 25 (12) 35 (17) 0.164
STEMI 3 (1) 9 (4) 0.079
NSTEMI 22 (10) 26 (12) 0.540
Cardiogenic shock 21 (10) 18 (9) 0.614
Atrioventricular block 8 (4) 5 (2) 0.398
Cardiomyopathy 36 (17) 36 (17) 1.000
Hyperkalemia 1 (0.5) 2 (0.9) 1.000
Hypokalemia 18 (9) 16 (8) 0.721
Stroke 9 (4) 8 (4) 0.804
Intracranial hemorrhage 0 (0) 1 (0.5) 1.000
Clinically significant bleeding 11 (5) 1 (0.5) 0.003
Anemia 20 (9) 6 (3) 0.005
Septic shock 5 (2) 0 (0) 0.061
Cardiac surgery 4 (2) 7 (3) 0.359
Table 1 Baseline characteristics and comorbidities after
propensity score matching (Continued)
Characteristic Non statin
(n = 212; 50%)
statin
(n = 212; 50%)
p value
Inadequate ICD shock 2 (0.9) 2 (0.9) 1.000
Atrial fibrillation 84 (40) 70 (33) 0.157
Paroxysmal 55 (26) 43 (20) 0.135
Persistent 9 (4) 3 (1)
Permanent 20 (9) 24 (11)
Asystole 5 (2) 9 (4) 0.277
PEA 2 (0.9) 0 (0) 0.499
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary
disease; ICD, implantable cardioverter- defibrillator; NSTEMI, non-ST segment
elevation myocardial infarction; PCI, percutaneous coronary intervention; PEA,
pulseless electrical activity; STEMI, ST segment myocardial infarction. Bold type
indicates p < 0.05
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Table 2 Cardiac diagnostics, therapies and survival data after propensity score matching
Characteristic No statin
(n = 212; 50%)
statin
(n = 212; 50%)
p value
Left ventricular ejection function, n (%)
LVEF ≥55% 63 (30) 60 (28) 0.352
LVEF 54–35% 63 (30) 62 (29)
LVEF < 35% 86 (41) 90 (43)
Cardiac therapies at index, n (%)
Cardiopulmonary resuscitation 61 (29) 51 (24) 0.271
In hospital 26 (12) 21 (10) 0.439
Out of hospital 35 (17) 30 (14) 0.500
External defibrillation 59 (28) 51 (24) 0.375
External cardioversion 13 (6) 9 (4) 0.381
Systemic thrombolysis 7 (3) 5 (2) 0.558
Targeted temperature management (TTM) 5 (2) 8 (4) 0.398
Coronary artery disease, n (%)
Coronary angiography, overall 131 (62) 140 (66) 0.363
Coronary artery disease, n (%)
No evidence of CAD 47 (36) 41 (29) 0.425
1-vessel 24 (18) 33 (24)
2-vessel 27 (21) 24 (17)
3-vessel 33 (25) 42 (30)
CTO 32 (24) 27 (19) 0.305
Presence of CABG 15 (12) 30 (21) 0.027
Intracoronary thrombus 2 (2) 6 (4) 0.180
CPR during coronary angiography 4 (3) 3 (2) 0.715
PCI, n (%) 28 (21) 43 (31) 0.081
Target lesions
RCA 11 (5) 16 (8) 0.320
LMT 1 (0.5) 0 (0) 1.000
LAD 15 (7) 18 (9) 0.587
RIM 0 (0) 0 (0) –
LCX 6 (3) 12 (6) 0.148
Bypass graft 0 (0) 3 (1) 0.248
Electrical therapies at index, n (%)
Electrophysiological examination 72 (34) 88 (42) 0.109
Catheter ablation 18 (9) 19 (9) 0.863
Newly implanted devices at index, n (%)
ICD 54 (26) 54 (26) 1.000
CRT-D 3 (1) 8 (4) 0.127
CRT-P 1 (0.5) 0 (0) 1.000
Pacemaker 4 (2) 2 (0.9) 0.685
Cardiac contractility modulation (CCM) 0 (0) 0 (0) –
Subcutaneous ICD 0 (0) 1 (0.9) 1.000
Overall implanted devices 124 (59) 121 (57) 0.768
Medication at discharge, n (%)
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0.302, 95% CI = 0.162–0.565, p = 0.001; LVEF < 35, 21%
vs 35%; log rank p = 0.089) (Fig. 2, left and right panel).
The presence of an activated ICD was associated with
a comparable lower subsequent mortality both in statin
(mortality rates: statin patients, 12% vs 21%, log rank p
= 0.040, HR = 0.493, 95% CI =0.247–0.2983, p = 0.045)
and non-statin patients (mortality rates: non-statin pa-
tients, 25% vs 44%, log rank p = 0.002, HR = 0.490, 95%
CI = 0.305–0.785, p = 0.003) (data not shown). Further-
more, irrespective of the presence or absence of acti-
vated ICD mortality was still lower in statin compared
to non-statin patients (mortality rates: ICD carriers, 12%
vs 25%, log-rank p = 0.007, HR = 0.429, 95% CI = 0.227–
0.804, p = 0.008; no ICD carrier, 21% vs 44%, log-rank
p = 0.002, HR = 0.439, 95% CI = 0.252–0.754, p = 0.003)
(Fig. 3, left & right panel).
Multivariable cox models
In multivariable Cox regression analysis, statin therapy
was still associated with a lower risk of all-cause mortal-
ity in patients presenting with ventricular tachyarrhyth-
mias (HR 0.508; CI 0.333–0.776, p = 0.002), comparable
to the presence of an activated ICD (HR 0.359, 95% CI
0.359; 95% CI 0.230–0.559; p = 0.002). Furthermore, pa-
tients’ age (HR 1.054), male gender (HR 1.382), CKD
(HR 1.356), LVEF < 35% (HR 1.803) and cardiogenic
Table 2 Cardiac diagnostics, therapies and survival data after propensity score matching (Continued)
Characteristic No statin
(n = 212; 50%)
statin
(n = 212; 50%)
p value
Beta-blocker 162 (76) 187 (88) 0.001
ACE-inhibitor 115 (54) 153 (72) 0.001
AT1-Antagonist 21 (10) 29 (14) 0.249
Aldosteron-antagonist 22 (10) 33 (16) 0.112
Aspirin only 58 (27) 78 (37) 0.037
Thienopyridine only 4 (2) 10 (5) 0.103
Dual antiplatelet therapy 25 (12) 52 (25) 0.001
Vitamin k antagonist 54 (26) 48 (23) 0.495
NOAC 7 (3) 2 (0.9) 0.175
Amiodarone 54 (26) 38 (18) 0.059
Digitalis 33 (16) 38 (18) 0.515
Hospitalization time, days, (median (IQR))
Total hospitalization time 16 (8–27) 14 (8–26) 0.009
ICU time 3 (0–11) 2 (0–7) 0.004
Follow-up time, days, (mean; median (range)) 1849; 1806
(25–5095)
1853; 1675
(18–5091)
0.013
All cause-mortality at 3 years, n (%) 70 (33) 33 (16) 0.001
CABG; coronary artery bypass grafting; CAD, coronary artery disease; CRT-D, cardiac resynchronization therapy plus defibrillator; CRT-P, cardiac resynchronization
therapy plus pacemaker; CTO, chronic total occlusion; LAD, left anterior descending; LCX, left circumflex; LVEF, left ventricular ejection function; ICD, implantable
cardioverter-defibrillator; ICU, intensive care unit; IQR, interquartile range; NOAC, new oral anticoagulants; PCI, percutaneous coronary intervention; RCA, right
coronary artery; RIM, Ramus intermedius. Bold type indicates p < 0.05
Fig. 1 Overall all-cause mortality comparing statin with non statin patients (first panel), according to the underlying ventricular tachyarrhythmias,
VT (second panel) and VF (third panel)
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shock (HR 1.512) were significantly associated with an
increased risk of long-term all-cause death. (Fig. 4).
Discussion
The present study evaluates the prognostic impact of
statin therapy on long-term survival in high-risk patients
surviving ventricular tachyarrhythmias on admission.
This real-world data suggests that the presence of statin
therapy is associated with a reduced risk of long-term
all-cause mortality. The prognostic benefit of a statin ther-
apy was evident irrespective of the underlying type of ven-
tricular tachyarrhythmias (VT or VF), LV dysfunction or
presence of an activated ICD. Additionally, the prognostic
benefit associated with statin therapy was still evident
even after controlling for patients’ age, gender, diabetes,
CKD, AMI, CAD, cardiogenic shock, CPR, LVEF < 35%
and presence of an activated ICD.
This study consistently identifies the presence of a sta-
tin therapy as a robust predictor of improved survival in
patients surviving malignant arrhythmia on hospital ad-
mission. The major strength of the present study con-
sists in the consecutive recruitment of patients with
ventricular tachyarrhythmias and documented statin
therapy straight from the admission scenario.
Several RCT and observational studies were able to
demonstrate that lipid lowering therapy, especially by the
use of statins, might lower all-cause mortality and cardio-
vascular death in patients with ischemic cardiomyopathy
or CAD [6, 7, 14, 15, 18]. Statins may also prevent future
SCD, reduce recurrences of ventricular tachyarrhyth-
mias and improve overall survival in patients suffering
from heart failure patients with LVEF < 30% [10, 15]. Not-
ably, there is only one RCT published by Vrtovec et al.
demonstrating that treatment with atorvastatin was able
to significantly reduce the incidence of future SCD in pa-
tients with LVEF < 30% and cholesterol levels > 150mg/dl
at one year of follow-up [24]. Furthermore, several obser-
vational sub-studies of randomized ICD/CRT trials
(MADIT II, MADIT-CRT, DEFINITE) demonstrated
improved survival and reduction of arrhythmic deaths in
patients treated with statins [10, 18, 19]. For instance, a
sub-study of the MADIT-CRT trial demonstrated a
significant reduction of appropriate ICD-therapies at 4
years in patients suffering from both ischemic and
Fig. 2 All-cause mortality comparing statin with non-statin patients according to LVEF ≥35% (left) and LVEF < 35% (right)
Fig. 3 All-cause mortality comparing statin with non-statin patients according to the presence (left) or absence of activated ICD (right)
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non-ischemic cardiomyopathy in the presence of statin
therapy. Unfortunately, no information was given on the
types and dosages of the administered statins [10]. An-
other sub-study of the DEFINITE trial found a reduced
rate of premature beats, non-sustained VT and arrhythmic
deaths in ICD carriers with non-ischemic cardiomyopathy
with statin therapy [19]. However, the major limitation of
these sub-studies is related to their preselected study co-
horts and their unmatched character regarding the use of
statins, which finally lead to further conflicting results in
the according meta-analyses [12, 13, 17].
The following pathophysiological concepts may explain
the beneficial effects of statin therapy in ventricular
tachyarrhythmias and SCD, which may lay beyond the sole
reduction of the atherosclerotic or ischemic burden.
Statins are inhibitors of the HMG-CoA reductase and do
reveal further pleiotropic pharmacological effects. These
comprise prevention of ischemia, primary antiarrhythmic
and anti-inflammatory effects [25]. The prevention of is-
chemia by statins was recently attributed to anti-coagulant
and anti-thrombogenic effects, which in turn may reduce
coronary micro-embolisms potentially causing myocardial
ischemia and alleviating the development of ventricular
tachyarrhythmias and SCD [25–28]. The anti-
inflammatory effects of statins are represented mainly by
their direct influence on atherosclerosis development. In-
flammation itself represents a relevant causal factor for
arrhythmogenesis [25, 29]. Within a community-based
RCT including 1702 patients without evidence of CVD,
statins were shown to reduce elevated CRP levels (C-re-
active protein), which may indirectly lead to reduced risk
of SCD [30, 31]. Furthermore, statins reveal direct
anti-arrhythmic effects [32]. The antiarrhythmic proper-
ties were observed in experimental mouse models, where
statins attenuated T-wave and Ca2+ alternans in isolated
ventricular cardiomyocytes of mice treated with statin
[33]. Both electrical disorders are precursors for an un-
stable electrical milieu alleviating the onset of malignant
ventricular arrhythmia [23–25].
The use of statins is usually investigated in clinical stud-
ies investigating preselected patient populations, such as
CAD, AMI, chronic heart failure or hyperlipidaemia,
Fig. 4 Statin therapy was still associated with beneficial survival even after adjusting for several prognosis-relevant factors
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which sets the present study in clear contrast to the
currently available evidence. The present study is based
on an unselected all-comers design, thereby including
“real-world” patients consecutively presenting on admis-
sion with life-threatening ventricular tachyarrhythmias,
and still demonstrated beneficial effects for prognosis as-
sociated with statin therapy in this “high-risk” cohort. The
findings were consistently and robustly demonstrated by
applying stepwise stratification within a propensity score
matched analysis. Underlying pathologies were strictly
matched for included AMI (14%), CAD (68%), cardiogenic
shock (10%), cardiomyopathy (17%) and atrial fibrillation
(36%).
There is only one study by De Sutter et al., which is
widely comparable to the data of the present study.
Here, CAD patients presenting at index with
life-threatening ventricular tachyarrhythmias were in-
cluded following secondary implantation of an ICD with
a mean follow-up of 490 days [34]. Only those patients
with lipid lowering therapy (defined as treatment with
both statins and fibrates) revealed less recurrences of
ventricular tachyarrhythmias as documented by applica-
tion of anti-tachycardia pacing (ATP) or shocks. The
study did not exclude patients with normal or mildly re-
duced LVEF. Accordingly, the present study delivers evi-
dence that statins may reveal beneficial effects also in
high-risk patients with ventricular tachyarrhythmias with
a still preserved left ventricular ejection fraction (LVEF
> 55, 30% in each matched group).
Therefore, the present results support the hypothesis
that statins may reveal several pleiotropic effects includ-
ing potential anti-arrhythmic properties, since a signifi-
cant reduction of secondary all-cause mortality was
demonstrated in unselected but well-matched all-comer
patients presenting with ventricular tachyarrhythmias on
hospital admission when treated with statins.
Study limitations
This observational and retrospective registry-based ana-
lysis reflects a realistic picture of consecutive health-care
supply of high-risk patients presenting with ventricular
tachyarrhythmias. Lost to follow-up rate regarding the
evaluated endpoint of all-cause mortality was minimal.
Additionally, heterogeneity within the study population
was controlled by a stepwise statistical approach includ-
ing multivariable adjustment for several important co-
morbidities and risk factors within a propensity matched
cohort. Patients not surviving out of hospital CPR and
not being transferred to the heart centre were not in-
cluded in this study. All clinical data was documented
reliably by individual cardiologists and specialists in in-
ternal medicine and cardiology during routine clinical
care being blinded to final data analyses, alleviating the
use of an independent clinical event committee.
Conclusions
Statin therapy is associated with decreased long-term
all-cause mortality in patients presenting with ventricu-
lar tachyarrhythmias.
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